# GPT 5.2 Review - Reviewer 3/3 (Parallel)

**Model:** gpt-5.2-2025-12-11
**Paper:** paper.pdf
**Reasoning effort:** medium
**Timestamp:** 2026-01-29T14:27:21.562840
**Review mode:** Parallel (3 independent reviewers)
**Response ID:** resp_0eca4c0b298fadc200697b5f87fb8c8193ab78010842e5a05a
**Tokens:** 18082 in / 5773 out
**Response SHA256:** 423e03ed6e9ce48d

---

## Referee Report (Top General-Interest Economics Journal Standard)

This manuscript is best characterized as a *data infrastructure + descriptive atlas* paper. That can be valuable, but top general-interest outlets (AER/QJE/JPE/ReStud/Ecta) and AEJ:EP will still require (i) a clearly articulated scientific contribution beyond “we built a dataset,” and—most importantly—(ii) **formal statistical inference** supporting any substantive claims. As written, the paper makes empirical assertions (cross-state differences; “visible discontinuities”; long-run declines) without a corresponding inferential framework. That is a first-order, publication-blocking problem.

Below I give a rigorous assessment along the dimensions requested.

---

# 1. FORMAT CHECK

### Length
- The manuscript appears to be **~25 pages of main text** (page 1–25) **plus references starting on p. 26** and appendices thereafter.  
- This **meets** the “≥25 pages excluding references/appendix” bar *barely*; however, for a top journal, 25 pages of largely descriptive material is typically not enough unless paired with a strong conceptual/statistical contribution.

### References coverage
- The bibliography is **thin** relative to the marijuana/traffic safety literature and relative to the econometrics of spatial RDD and policy DiD.
- It cites a few core items (Anderson et al. 2013; Keele & Titiunik 2015; Callaway & Sant’Anna 2021; Sun & Abraham 2021), but omits many foundational and closely related papers (details in Section 4 below).  
- **FAIL for adequacy** for a top journal positioning.

### Prose vs bullets
- Most major sections are written in paragraphs (e.g., Introduction p. 1–2; Data p. 3–8; Discussion p. 23).  
- However, there is **heavy reliance on bullet lists** throughout Section 2 and Appendix A (variable definitions), which is acceptable in Data/Appendix, but some bullets creep into interpretive discussion (e.g., mechanisms in Section 8.4, p. 22–23 reads like a memo). Tighten and convert key interpretive parts into prose.

### Section depth (3+ substantive paragraphs each)
- **Introduction (Section 1)**: yes (multiple paragraphs).
- **Data (Section 2)**: yes, though much is procedural.
- **Descriptive patterns (Sections 3–6)**: mixed. Some subsections are short or figure-driven with limited interpretation.
- **Discussion (Section 9)**: yes, but largely caveats (good to flag, but it’s doing too much work because identification is absent).

### Figures
- Most figures have visible data and labeled axes (e.g., Fig 1–4).  
- Maps (Fig 5–8) are visually informative but not yet publication-grade for a top journal:
  - Legends/notes are long but still leave ambiguity (e.g., what exactly is the plotted denominator set on each map).
  - Some maps lack clear axis ticks (acceptable for maps), but **need consistent scale bars, north arrows, and consistent symbology** across figures.
  - Use colorblind-safe palettes (red/green contrasts appear in Appendix Fig 15).

### Tables
- Table 1 and Table 2 have real numbers and coherent notes.  
- Table 2 has a **labeling error**: “Panel D” appears before “Panel C” (p. 7). Also Table 2 mixes periods (2001–2005; 2016–2019; then 2018–2019) in a confusing way.

**Format bottom line:** Fixable presentation issues exist, but the paper’s main barrier is not format—it is the lack of inferential econometrics.

---

# 2. STATISTICAL METHODOLOGY (CRITICAL)

The paper **does not meet minimum standards for publishable empirical economics in a top journal**.

### (a) Standard errors
- There are **no regression tables** and **no coefficients with SEs** anywhere.
- The manuscript reports differences like “~20% vs ~10%” and claims “visible discontinuities” (Abstract; Sections 3, 6; Appendix Fig 15) without reporting uncertainty.

**Result: FAIL.** Under your own criteria, this is unpublishable.

### (b) Significance testing
- No hypothesis tests (no t-tests, no randomization inference, no permutation tests, no clustered SEs, no spatial HAC, nothing).

**FAIL.**

### (c) Confidence intervals
- Some figures show LOESS bands (Appendix Fig 15), but LOESS shading is **not** a substitute for design-based causal inference, and it is not consistently presented for main results.

**FAIL** for main results.

### (d) Sample sizes
- Some figures list N (e.g., Fig 5 “N=1353 crashes with any drug record”), but there are **no regression Ns** because there are no regressions. For a policy paper, Ns must be reported for every estimate and every bandwidth/bin used.

**FAIL** for inferential estimates.

### (e) DiD with staggered adoption
- The paper discusses DiD (Section 8.2, p. 21–22) and staggered adoption issues, but it **does not implement any DiD estimator**.  
- It also admits missing years 2006–2015, preventing credible event studies. That is a major obstacle to any DiD contribution.

As written: **N/A operationally**, but if the authors later implement DiD, they must avoid naive TWFE and use modern estimators, plus show pre-trends.

### (f) RDD requirements
- The paper repeatedly motivates “spatial RDD” (Abstract; Sections 4.1, 8.1; Appendix Fig 15) but does not implement an RDD:
  - No bandwidth choice discussion (IK/CCT).
  - No robustness to bandwidths/kernels/polynomial order.
  - No McCrary density test adapted to spatial running variables (or analog: testing discontinuities in crash density / covariates at border).
  - No covariate balance / continuity checks.

**FAIL.**

### Publishability implication
Because the paper makes policy-relevant claims but provides **no formal inference**, it is **not publishable in its current form** at the journals listed. Even as a “data paper,” top econ journals generally require either (i) an econometric/methodological contribution with proofs/validation, or (ii) substantive causal results.

---

# 3. IDENTIFICATION STRATEGY

### What is the identification claim?
- The manuscript explicitly says it is “methodological and descriptive rather than causal” (Section 1, p. 2). That is coherent, but it conflicts with:
  - The Abstract’s language (“discontinuities… motivating spatial RDD designs”).
  - Repeated suggestions consistent with causal interpretation (“policy discontinuity,” “estimate causal effects,” etc.).
  - The concluding framing (“foundation for rigorous causal research,” p. 24–25) is fine, but then the paper should **avoid causal-sounding descriptive claims** or back them with inference.

### Credibility and assumptions
- **DiD**: Parallel trends cannot be evaluated because 2006–2015 are missing (p. 21–22). Without those years, any pre/post comparison across 2001–2005 vs 2016–2019 is vulnerable to confounding by:
  - secular trends in drug testing/reporting,
  - changes in road safety, vehicle safety tech,
  - opioid/meth trends,
  - smartphones/distracted driving,
  - Great Recession driving exposure changes,
  - changes in policing and toxicology labs.

- **Spatial RDD**: Continuity assumptions at borders are plausible in some contexts but not automatic. Many borders in the West are:
  - extremely rural with non-comparable road networks,
  - have different enforcement regimes,
  - have different trauma system access (affecting fatality conditional on crash),
  - have different testing/reporting (central concern here).
  The paper does not (yet) test any of these continuity conditions.

### Placebos / robustness
- None implemented. At minimum, the paper should show:
  - discontinuities for outcomes that *should not* change at legalization borders (e.g., weather, daylight, road class composition, vehicle age composition) to diagnose sorting/compositional change;
  - discontinuities in *drug-reporting propensity* itself (crash has any drug record), because selection into the drugs file is central (Section 7).

### Do conclusions follow?
- The conclusions are mostly cautious, but several statements still read as if legalization is the driver of differences. Without inference and without addressing selection into testing/reporting, the “20% vs 10%” difference is **not interpretable** as an effect.

---

# 4. LITERATURE (MISSING REFERENCES + BibTeX)

The paper needs a much stronger positioning in **three literatures**: (i) marijuana legalization and traffic safety, (ii) RDD (especially geographic/spatial RDD practice), and (iii) modern DiD and policy evaluation diagnostics.

Below are *specific* missing references with short rationales and BibTeX.

---

## (A) Marijuana legalization & traffic safety (empirical)
You cite Anderson et al. (2013) and Hansen et al. (2015), but omit major work directly on recreational legalization and fatalities.

1) **Santaella-Tenorio et al. (2017)** — comprehensive review/meta-evidence on cannabis and driving; essential to frame impairment vs detection.
```bibtex
@article{SantaellaTenorio2017,
  author  = {Santaella-Tenorio, Jessica and Mauro, Christine M. and Wall, Melanie M. and Kim, Jeesun H. and Cerda, Magdalena and Keyes, Katherine M. and Hasin, Deborah S. and Martins, Silvia S.},
  title   = {US traffic fatalities, 1985--2014, and their relationship to medical marijuana laws},
  journal = {American Journal of Public Health},
  year    = {2017},
  volume  = {107},
  number  = {2},
  pages   = {336--342}
}
```

2) **Aydelotte et al. (2017)** — early evidence on fatalities after recreational legalization (CO/WA era), widely cited in policy debates.
```bibtex
@article{Aydelotte2017,
  author  = {Aydelotte, J. D. and Brown, L. H. and Luftman, K. M. and Mardock, A. L. and Teixeira, P. G. and Coopwood, T. B. and Brown, C. V. R.},
  title   = {Crash fatality rates after recreational marijuana legalization in Washington and Colorado},
  journal = {American Journal of Public Health},
  year    = {2017},
  volume  = {107},
  number  = {8},
  pages   = {1329--1331}
}
```

3) **Hansen, Miller, Weber (2020-ish line of work)** — several papers on rec legalization and outcomes; at minimum, discuss recreational vs medical differences (your policy timing table is a start but not enough).

4) **Sevigny (and coauthors)** on cannabis-impaired driving measurement and FARS toxicology comparability (your Section 7 cries out for measurement references).

---

## (B) RDD (foundational + robust inference)
Keele & Titiunik (2015) is not enough. Top-journal readers will expect canonical RDD citations and modern robust RDD practice.

1) Imbens & Lemieux (2008)
```bibtex
@article{ImbensLemieux2008,
  author  = {Imbens, Guido W. and Lemieux, Thomas},
  title   = {Regression discontinuity designs: A guide to practice},
  journal = {Journal of Econometrics},
  year    = {2008},
  volume  = {142},
  number  = {2},
  pages   = {615--635}
}
```

2) Lee & Lemieux (2010)
```bibtex
@article{LeeLemieux2010,
  author  = {Lee, David S. and Lemieux, Thomas},
  title   = {Regression discontinuity designs in economics},
  journal = {Journal of Economic Literature},
  year    = {2010},
  volume  = {48},
  number  = {2},
  pages   = {281--355}
}
```

3) Calonico, Cattaneo & Titiunik (2014) — robust bias-corrected inference (CCT)
```bibtex
@article{CalonicoCattaneoTitiunik2014,
  author  = {Calonico, Sebastian and Cattaneo, Matias D. and Titiunik, Rocio},
  title   = {Robust nonparametric confidence intervals for regression-discontinuity designs},
  journal = {Econometrica},
  year    = {2014},
  volume  = {82},
  number  = {6},
  pages   = {2295--2326}
}
```

4) McCrary (2008) — manipulation/density test
```bibtex
@article{McCrary2008,
  author  = {McCrary, Justin},
  title   = {Manipulation of the running variable in the regression discontinuity design: A density test},
  journal = {Journal of Econometrics},
  year    = {2008},
  volume  = {142},
  number  = {2},
  pages   = {698--714}
}
```

You should also cite work on **spatial/geographic RDD implementation details** beyond Keele–Titiunik (e.g., border-pair methods in economics).

---

## (C) DiD (modern pitfalls + diagnostics)
You already cite Callaway–Sant’Anna and Sun–Abraham, good. But you are missing the “TWFE decomposition / forbidden comparisons” canon that any AEJ:EP/top-journal referee will demand.

1) Goodman-Bacon (2021)
```bibtex
@article{GoodmanBacon2021,
  author  = {Goodman-Bacon, Andrew},
  title   = {Difference-in-differences with variation in treatment timing},
  journal = {Journal of Econometrics},
  year    = {2021},
  volume  = {225},
  number  = {2},
  pages   = {254--277}
}
```

2) de Chaisemartin & D’Haultf{\oe}uille (2020)
```bibtex
@article{deChaisemartinDHaultfoeuille2020,
  author  = {de Chaisemartin, Cl{\'e}ment and D'Haultf{\oe}uille, Xavier},
  title   = {Two-way fixed effects estimators with heterogeneous treatment effects},
  journal = {American Economic Review},
  year    = {2020},
  volume  = {110},
  number  = {9},
  pages   = {2964--2996}
}
```

3) Roth et al. (2023) on pretrend testing / event-study diagnostics is increasingly standard in AEJ:EP-style policy papers.
```bibtex
@article{RothSantAnnaBilandzic2023,
  author  = {Roth, Jonathan and Sant'Anna, Pedro H. C. and Bilinski, Alyssa and Poe, John},
  title   = {What's trending in difference-in-differences? A synthesis of the recent econometrics literature},
  journal = {Journal of Econometrics},
  year    = {2023},
  volume  = {235},
  number  = {2},
  pages   = {2218--2244}
}
```

---

# 5. WRITING QUALITY (CRITICAL)

### (a) Prose vs bullets
- Generally acceptable in the Introduction and narrative sections.
- However, interpretive sections (esp. **Section 8.4 Mechanism Analysis**, p. 22–23) read like internal notes: short bullet-like paragraphs with colons (“Time-of-day patterns: … Road-type heterogeneity: …”). For a top journal, convert these into cohesive prose and link them to concrete estimands and figures.

### (b) Narrative flow
- The paper has a clear “data → descriptive patterns → border maps → limitations → applications” structure.
- The *hook* is not strong enough for a general-interest journal: the Introduction (p. 1–2) motivates importance, but the paper needs a sharper statement of:
  - **Who cannot answer what today because this dataset doesn’t exist?**
  - **What new empirical fact is learned immediately from the integration** (with uncertainty quantified)?
- Right now it reads closer to a technical report than a general-interest contribution.

### (c) Sentence-level quality
- Competent, but often repetitive (“This visualization motivates…” appears multiple times).
- Too many caveats appear *after* bold descriptive claims; better practice is: define estimand → show evidence → interpret → caveat.

### (d) Accessibility
- Good explanations of FARS limitations (Section 2.1, 7; Appendix A).
- But the key methodological issue—**selection into drug reporting**—is so central that it should be introduced earlier and framed as a first-order measurement problem, not a later limitation.

### (e) Figures/Tables publication quality
- Figures are legible in the provided pages, but not yet “journal-ready”:
  - enforce consistent typographic hierarchy;
  - harmonize color schemes across all plots;
  - ensure every figure note defines the denominator precisely (especially drug-record conditioning).

---

# 6. CONSTRUCTIVE SUGGESTIONS (HOW TO MAKE THIS TOP-JOURNAL IMPACTFUL)

To have a plausible path to AEJ:EP/top-field, you need to add **credible estimation + inference** and/or a **methodological validation** that rises above descriptive cartography.

## A. Add a main causal design with full inference (choose one, execute perfectly)

### Option 1: Border-based spatial RDD (your natural comparative advantage)
Deliver a full RDD analysis with:
- Estimand: discontinuity in (i) THC-detection conditional on drug-record, (ii) drug-record propensity itself, (iii) alcohol involvement, (iv) fatalities per crash, etc.
- Running variable: signed distance to border; define border segments and pre-register border-pair selection rules.
- Estimation: local linear with CCT robust bias-corrected CIs; cluster at border-segment or use randomization inference by spatial block.
- Diagnostics:
  - covariate continuity plots/tables;
  - density test analog: test discontinuity in crash density (or in geocoding probability) at the border;
  - bandwidth sensitivity (multiple bandwidths);
  - placebo borders (borders between two illegal states; or pre-period where policy is identical on both sides);
  - “donut” RDD excluding within X km of the border if there is sorting in travel/shopping.

Crucially: **your outcome is not “THC-positive” in the population.** It’s “THC finding among those with drug findings reported.” That selection must be modeled or bounded.

### Option 2: Staggered DiD with full panel years
Your own text admits missing years 2006–2015 prevent event studies (p. 21–22). Fix that by extending the pipeline to **all years 2001–2019 (or 2001–2023)** and then implement:
- Callaway–Sant’Anna (group-time ATT) with never-treated controls (e.g., WY/ID/UT/KS/NE).
- Event-study plots with pretrend diagnostics.
- Sensitivity to alternative treatment timing: possession legal vs retail opening (Table 1 suggests both matter).
- Explicit exposure measure: crashes per VMT or per population at county level (raw crash counts are hard to interpret spatially).

## B. Treat drug testing/reporting as an endogenous measurement process
Right now the paper correctly notes the drugs file is incomplete (Section 7) but stops there. For publishable inference, do at least one of:

1) **Two-equation / selection approach**  
Model:
- first stage: probability crash has any drug record (selection),
- second stage: THC finding conditional on having a record.
Use IPW or Heckman-style sensitivity, acknowledging identification limits.

2) **Bounding**  
Provide Manski-style bounds for THC prevalence allowing for differential testing rates across states. Even partial identification would be a real methodological contribution.

3) **Validation against external toxicology sources**  
If possible, validate FARS THC detection against state toxicology labs / medical examiner data for one or two states.

## C. Rebuild the policy exposure definition
- You classify “legal states” as CO/WA/OR/AK/CA/NV even in years when CA (2016) and NV (2016) were not legal (Table 2 note, p. 7–8; Figure 3 note). This is fine for purely descriptive grouping, but **it is not acceptable for any causal analysis** and can mislead readers even descriptively. Recode by crash-date legal status everywhere except perhaps one clearly labeled descriptive appendix.

## D. Improve the contribution statement
For a top journal, “we provide replication code” is not enough. You need one of:
- a new causal estimate that is more credible than existing work, *because* it leverages border microgeography and road attributes; or
- a new methodological result about inference with geocoded administrative crashes and endogenous toxicology reporting.

---

# 7. OVERALL ASSESSMENT

### Key strengths
- Ambitious and useful data integration: FARS + OSM road attributes + policy timing.
- Clear documentation of limitations (especially drug-reporting selection and THC impairment vs detection).
- The border-map visualizations (Section 4; Appendix) show the dataset could support serious spatial designs.

### Critical weaknesses (publication-blocking)
1) **No statistical inference**: no SEs, no CIs, no tests, no regression framework—yet the paper draws comparative conclusions. This fails minimal standards for AEJ:EP/top-5 empirical work.  
2) **No implemented identification strategy**: RDD and DiD are discussed, not executed.  
3) **Measurement/selection problem is central and unresolved**: conditioning on “crashes with any drug record” is not innocuous; cross-state differences may reflect reporting regimes more than behavior.  
4) **Literature positioning is incomplete**: missing key empirical and econometric references expected by general-interest audiences.  
5) **Policy coding and time coverage issues**: missing 2006–2015 severely limits credibility of any temporal policy evaluation; grouping legal states by eventual status is potentially misleading.

### Specific actionable improvements
- Add full-period data (2001–2019 continuous) and implement either C&S DiD or CCT RDD with full diagnostics and CIs.
- Treat drug-reporting propensity as an outcome and/or a selection process.
- Expand literature review substantially (add the missing RDD/DiD canon + marijuana/traffic work).
- Rewrite Section 8 (applications) into a tighter, prose-driven roadmap tied to estimands and feasible analyses, not a list of possibilities.

---

**DECISION: REJECT AND RESUBMIT**